REMARKS

Applicants have canceled claims 1-39 of record and have added claims 40-52 drawn to certain preferred embodiments of the present application.

Independent claim 40 is directed to a method for the treatment of Huntington's Disease (HD) or symptoms thereof in a subject by administering to the subject an effective amount of Clioquinol (CQ) or a pro-drug thereof or a salt of CQ. As disclosed in the present application, CQ is a preferred agent for treating a neurological disorder. See, e.g., at page 9, lines 13-14; and page 14, lines 12-13. HD is one of the neurological disorders contemplated by the present invention. See, e.g., page 32, line 3. Support for the recitations "prodrug" and "salt" is found, e.g., at page 11, lines 4-5 of the specification.

Dependent claim 41 further characterizes the symptoms as comprising "cognitive impairment or memory loss". Support for claim 2 is found throughout the specification, e.g., at page 9, first paragraph.

Dependent claims 42-43 delineate embodiments where CQ or a pro-drug or a salt of CQ is administered with at least one other compound useful for treating a neurological disorder. Claims 42-43 are supported by original claims 17-18.

Dependent claims 47-52 further delineate the dosage ranges of CQ or a pro-drug or a salt of CQ, and are supported by the specification, e.g., at page 33, lines 29-30.

Applicants respectfully submit that the foregoing amendments do not introduce new matter.

Respectfully submitted,

Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530-3319
(516) 743-4242 (XZ:ab)